莪术油腹腔灌注联合TP方案治疗晚期上皮性卵巢癌的疗效观察OA
Efficacy Observation of Zedoary Turmeric Oil Intraperitoneal Perfusion Combined with TP Regimen in the Treatment of Advanced Epithelial Ovarian Cancer
目的 探讨莪术油腹腔灌注联合 TP 方案(紫杉醇+顺铂)对比单纯 TP 方案治疗晚期上皮性卵巢癌的临床疗效及安全性.方法 选取我院收治的240 例晚期上皮性卵巢癌患者作为研究对象,采用随机数字表法分为观察组与对照组,各120 例.对照组给予常规 TP 方案静脉化疗,观察组在对照组基础上联合莪术油注射液腹腔灌注治疗.比较两组患者的近期疗效、治疗前后血清学指标(CA125、HE4 水平)及免疫学指标(CD4+、CD8+、CD4+/CD8+)、CT 影像肿瘤体积变化、药物不良反应发生率,并通过随访比较两组患者的无进展生存期(PFS)和总生存期(OS).结果 观察组患者的客观缓解率(ORR)和疾病控制率(DCR)显著高于对照组(P 均<0.05).治疗后,两组患者血清 CA125、HE4 水平均较治疗前下降,且有显著差异(P 均<0.05);观察组 CD4+细胞和 CD4+/CD8+比值均显著高于对照组,CD8+T 细胞显著降低(P 均<0.05).CT 显示观察组肿瘤体积缩小更显著(P<0.05).在安全性方面,两组在血液学毒性、肝肾功能损伤等主要不良反应发生率上无统计学差异(P 均>0.05),观察组未增加额外严重不良反应.随访结果显示,中位无进展生存期(18 个月 vs.12 个月)和中位总生存期(32 个月 vs.24 个月)均长于对照组(P 均<0.05).结论 莪术油腹腔灌注联合 TP 方案治疗晚期上皮性卵巢癌,能有效提高近期疗效,降低肿瘤标志物水平,改善患者机体免疫功能,延长生存期,且不增加化疗相关毒副反应,安全性良好,值得临床推广应用.
Objective To investigate the clinical efficacy and safety of Zedoary Turmeric Oil intraperitoneal perfusion combined with the TP regimen(Paclitaxel+Cisplatin)compared with the TP regimen alone in the treatment of advanced epithelial ovarian cancer.Meth-ods A total of 240 patients with advanced epithelial ovarian cancer admitted to our hospital were selected as the study subjects and randomly divided into an observation group and a control group,with 120 cases in each group.The control group received conventional intravenous chemotherapy with the TP regimen.The observation group received intraperitoneal perfusion of Zedoary turmeric oil injection in addition to the TP regimen.The short-term efficacy,serological indicators(CA125,HE4 levels),immunological indicators(CD4+,CD8+T cell ratios,and CD4+/CD8+ratio),CT-based tumor volume changes,incidence of adverse drug reactions were compared between the two groups before and after treatment,with progression-free survival(PFS),and overall survival(OS)assessed through follow-up.Results The objective re-sponse rate(ORR)and disease control rate(DCR)in the observation group were significantly higher than those in the control group(all P<0.05).After treatment,serum CA125 and HE4 levels decreased in both groups compared to before treatment,and showed significant differ-ences(all P<0.05).The proportions of CD4+T cells and the CD4+/CD8+ratio in the observation group were significantly higher,whereas CD8+T cells were significantly lower compared to in the control group(all P<0.05),CT imaging showed more significant tumor volume reduction in the observation group(P<0.05).Regarding safety,there was no statistically significant difference in the incidence of major ad-verse reactions such as hematological toxicity and liver/kidney function impairment between the two groups(all P>0.05),and the observa-tion group did not exhibit additional severe adverse reactions.Follow-up results showed that both median progression-free survival(18 months vs.12 months)and median overall survival(32 months vs.24 months)were longer in the observation group than those in the control group(all P<0.05).Conclusion Zedoary Turmeric Oil intraperitoneal perfusion combined with the TP regimen for advanced epithelial ovari-an cancer can effectively improve short-term efficacy,reduce tumor marker levels,enhance patients'immune function,prolong survival,and does not increase chemotherapy-related toxic side effects,demonstrating good safety and being worthy of clinical application and promotion.
王灵霞;柯怀
阳新县人民医院妇产科,湖北 阳新 435200阳新县人民医院妇产科,湖北 阳新 435200
医药卫生
上皮性卵巢癌晚期莪术油腹腔灌注TP方案疗效生存分析
Epithelial ovarian cancerAdvanced stageZedoary Turmeric OilIntraperitoneal perfusionTP regimenEfficacySur-vival analysis
《湖北科技学院学报(医学版)》 2026 (4)
327-331,5
评论